Search
Marnetegragene autotemcel
go.drugbank.com/drugs/DB17595Approved[L56116, A275467] Allogeneic hematopoietic stem cell transplant is a curative option but is limited by issues such as donor availability, a high incidence of graft-versus-host disease, and graft failure
Tetradecyl hydrogen sulfate (ester)
go.drugbank.com/drugs/DB11328ApprovedSodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose veins . Sodiu...
Methotrexate
go.drugbank.com/drugs/DB00563ApprovedInvestigational[A180322] Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma
Mupirocin
go.drugbank.com/drugs/DB00410ApprovedInvestigationalVet approved[L10580] It primarily works by inhibiting bacterial protein synthesis. … _ and traumatic skin lesions due to secondary skin infections caused by _S. aureus_ and _S. pyogenes_.
Normethadone
go.drugbank.com/drugs/DB11609ApprovedIllicitIt is marketed in Canada by Valeant under the tradename Cophylac.
Florquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease
Paraldehyde
go.drugbank.com/drugs/DB09117ApprovedWithdrawnParaldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo … Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello.
Fluoxymesterone
go.drugbank.com/drugs/DB01185ApprovedIllicitAn anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women.
International brands: U-GonoAcoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigational[A264808] It was brought to market by BridgeBio Pharma and approved by the FDA in November 2024 to reduce negative cardiovascular outcomes in patients with cardiomyopathy caused by TTR amyloidosis.
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalby the U.S. … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved